- Omega-3 may be the key to breaking through the blood-brain barrier (BBB)
- 2021 ASCO: Diagnosis and treatment of non-small cell lung cancer
- Leukemia (AML): Bristol-Myers Squibb Onureg was approved by EU
- Diet can change intestinal and breast flora and affects breast cancer risk
- WHO: Delta variant will become the world main popular variant virus strain
- Clinical application of interleukin in tumor immunotherapy
Research reveals a new mechanism for tumor-associated macrophages to regulate the fate of CD8+ T cells
New mechanism of Tumor-associated macrophages regulate CD8+ T cells. Tumor immunotherapy brings new treatment methods and hopes to cancer patients, and has been successfully applied in a variety of tumor types. Some patients can respond to immunotherapy and achieve the desired therapeutic effect, but most patients cannot respond to immunotherapy.
One of the important reasons is that the function of T cells in the tumor microenvironment has been in an irreversible disorder. Studies have shown that tumor-associated macrophages are one of the main forces that induce T cell dysfunction.
As a member of immune cells, macrophages are often affected by tumors after entering the tumor microenvironment, and transform into a state that promotes tumor growth and inhibits T cell function, but its regulatory mechanism is still unclear.
As the most abundant type of modification on mRNA in eukaryotic cells, m6A modification can precisely regulate cell function through processes such as affecting mRNA stability and translation efficiency. However, recent work has also found that the m6A modification system is in a state of imbalance in many types of tumors.
So, does m6A modification affect the function of tumor-associated macrophages and participate in the regulation of T cell function?
Researcher of the Beijing Institute of Genomics of the Chinese Academy of Sciences (National Center for Bioinformatics) Han Dali’s research group and Xu Meng’s team, researcher of the Institute of Immunology of Tsinghua University, published the title The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages The research paper promotes CD8+ T cell dysfunction and tumor growth reveals a new mechanism for specific tumor-associated macrophages to regulate CD8+ T cell function at the epitranscriptome level: the role of m6A methylase METL14 in C1q+ macrophages Loss, resulting in the decrease of m6A modification on the Ebi3 transcript in macrophages and the increase of EBI3 expression, which in turn induces the dysfunction of tumor-infiltrating CD8+ T cells.
Studies have found that there is a subgroup of C1q+ macrophages in tumor-associated macrophages, which interact with T cells through immunomodulatory receptors on the surface. Genes related to m6A modification are enriched in the C1q+ macrophage subpopulation (such as Mettl14).
Further exploring the role of m6A modification in macrophages, the researchers found that the anti-tumor ability of mice that specifically knocked out Mettl14 in macrophages was lower than that of wild-type mice, and the proportion of CD8+ T cells infiltrated by tumors was significantly reduced. Single-cell sequencing data showed that, compared with the wild-type control group, the absence of Mettl14 in macrophages can lead to a significant reduction in the infiltrating effector CD8+ T cells and exhaustive T cell precursor cells in the immune microenvironment, while the activation is abnormal and The dysfunctional intermediate CD8+ T cells increased significantly.
Functional verification further demonstrated that the absence of Mettl14 in macrophages resulted in a decrease in the killing function of CD8+ T cells and up-regulated the expression of co-inhibitory receptors. These results indicate that macrophages lacking Mettl14 break the balance of CD8+ T cell differentiation, that is, inhibit the activation of effector CD8+ T cells and promote CD8+ T cell dysfunction.
Through integrated analysis of the m6A-seq and RNA-seq data of tumor-associated macrophages with wild-type and Mettl14 deletion, it was found that the level of m6A modification on Ebi3 mRNA was significantly reduced in macrophages with Mettl14 deletion, and Ebi3 mRNA level and protein expression were significantly reduced.
The level has increased significantly. EBI3 neutralizing antibody can significantly improve its anti-tumor ability by saving the killing function of CD8+ T cells in Mettl14 conditional knockout mice. The results showed that macrophages lacking Mettl14 induced CD8+ T cell dysfunction by increasing the expression of EBI3. In order to explore whether the above conclusions are applicable to patient tumor samples, the researchers first used multicolor immunohistochemical staining techniques to find the close relationship between macrophages and CD8+ T cells in tumor samples of colon cancer patients.
In addition, the expression of METL14 in the tumor stroma was positively correlated with the level of m6A modification and the infiltration of CD8+ T cells. Compared with patients with a low level of m6A modification, the CD8+ T cells infiltrated in the tumor stroma have better effector functions.
In summary, this study reported a new mechanism for the dysregulation of RNA m6A modification in tumor-associated macrophages that leads to the up-regulation of EBI3 expression and promotes the dysfunction of CD8+ T cells.
Studies have shown that m6A modification regulates the immunoregulatory function of macrophages at the epitranscriptional level, emphasizing that the plasticity of macrophages can be precisely regulated through dynamic changes in epitranscription.
Researchers proposed that molecules that target the downstream of Mettl14 to inhibit CD8+ T cell function (such as EBI3) are expected to restore CD8+ T cell function and improve the response rate of existing PD-1/PD-L1 blocking antibody therapies.
(source:internet, reference only)